This finding resonates with previous reports on c-Met as a cancer therapy target, further emphasizing the importance of targeted immunotherapy strategies (Remon et al. 2023; Yoshida et al. 2022; Dong et al. 2022). The gene discussed is MET; the disease is cancer.